Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L BhattMichael SzarekPhillippe Gabriel StegChristopher P CannonLawrence A LeiterDarren K McGuireJulia B LewisMatthew C RiddleAdriaan A VoorsMarco MetraLars H LundMichel KomajdaJeffrey M TestaniChristopher S WilcoxPiotr PonikowskiRenato D LopesSubodh VermaPablo LapuertaBertram Pittnull nullPublished in: The New England journal of medicine (2020)
In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).